Isotechnika Pharma appoints Dr. Jurgen Engel to Board of Directors
Isotechnika Pharma Inc. announced that it has appointed Dr. Jurgen Engel to its Board of Directors. Dr. Engel is currently the President and CEO of AEterna Zentaris, where he has been since the acquisition of Zentaris in December 2002. A seasoned professional in the pharmaceutical industry, he brings extensive expertise in drug development and commercialization and partnership development. Prior to AEterna Zentaris he was CEO of Zentaris, a spin-off of ASTA Medica, AG, where he oversaw all Research and Development activities, supervised more than 700 scientists and clinical professionals, and successfully headed projects from drug discoveries to New Drug Applications.
Dr. Engel earned a doctorate degree in organic chemistry from the Technical University of Braunschweig, as well as an academic degree in pharmaceutical science from the University of Regensburg, where he is also a professor. In 1995, he was recognized for his development of alkylphospholipids as a new class of anti-tumor agents by receiving the Galenus-von-Pergamon Prize, an award that honors innovators in novel medicines.
Other news from the department people
